Padmapriyadarsini, CNair, DGomathi, N SVelayudham, B2017-01-042017-01-042016-10Padmapriyadarsini C, Nair D, Gomathi N S, Velayudham B. Pulmonary Mycobacterium kansasii disease in immunocompetent host: Treatment outcomes with short‑course chemotherapy. Indian Journal of Medical Microbiology. 2016 Oct-Dec; 34(4): 516-519.http://imsear.searo.who.int/handle/123456789/181119Mycobacterium kansasii, most virulent of all atypical mycobacteria, causes pulmonary disease identical to the disease caused by Mycobacterium tuberculosis. Early identification of the species and prompt initiation of treatment for M. kansasii is necessary to prevent morbidity and mortality due to this disease. This case series highlights the similarity in the clinical presentation of both M. tuberculosis and M. kansasii and response to direct observation of short‑course chemotherapy with rifampicin, in the management of pulmonary M. kansasii disease. Larger studies are required to evaluate the long‑term effect of short‑course chemotherapy, especially use of moxifloxacin, in the management of pulmonary M. kansasii disease.enMoxifloxacinpulmonary Mycobacterium kansasiirifampicinshort‑course chemotherapyArticle